Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Year: 2026
Type: erratum
Abstract: Following the publication of this article, the authors noted the following sentence could be misinterpreted: ‘In patients with ALK– sALCL, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5–70.2%) and 56.0% (39.3–69.7%) in the A + CHP and CHOP arms, respectively’. This sentence is in fact about patients with ALK– sALCL who achieved a complete response (CR), and while the sentence appears in the context of a paragraph discussing patients with a CR, the following correction has been made to avoid confusion: ‘In patients with ALK– sALCL who achieved CR, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5–70.2%) and 56.0% (39.3–69.7%) in the A + CHP and CHOP arms, respectively’. Data showing 5-year PFS in patients with ALK– disease, regardless of response, appear in Figure 1.
Source: Blood Cancer Journal
Authors: Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage
Institutions: Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Northwestern University, Columbia University Irving Medical Center, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Memorial Sloan Kettering Cancer Center, Universitätsmedizin Göttingen, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, Washington University in St. Louis, Odense University Hospital, Samsung Medical Center, Sungkyunkwan University, Hackensack Meridian Health, National Hospital Organization Kyushu Cancer Center, Ospedale Papa Giovanni XXIII, Charles University, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Cellectar Biosciences (United States), University of Debrecen, Istituto di Ematologia di Bologna, University of Bologna, Essen University Hospital, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Laboratoire d'imagerie translationnelle en oncologie, Institut Curie, Cleveland Clinic, University of Rochester Medicine, University of Rochester, Cogent Biosciences (United States), Vertex Pharmaceuticals (United States), Seagen (United States), BC Cancer Agency
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W7125976460
Cites:
Cited by:
Related to: